CTLA4 and glioblastoma: In a glioblastoma stem cell (GSC) mouse model, triple combination therapy with anti-CTLA-4, anti-PD-1 and an IL-12 expressing oncolytic virus (G47Δ-mIL12) cured 89% of mice, with 100% of the cured mice alive at 96 days post-tumor re-challenge, suggesting establishment of immunological memory with this combination therapy (50).